Literature DB >> 4051456

Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management.

R Tandan, W G Bradley.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease of the motor system in adults that occurs in sporadic, familial, and Western Pacific forms. Involvement of non-motor pathways has been increasingly recognized, both clinically and pathologically. Although the usual course is relentlessly progressive with death in half the cases within three years from onset, it can sometimes be protracted. Degeneration and loss of large motor neurons in the cerebral cortex, brainstem, and cervical and lumbar spinal cord are characteristic. Marked reduction in the number of large myelinated fibers is notable in the cervical and lumbar ventral roots. Peripheral nerves show reduced numbers of large myelinated fibers, acute axonal degeneration at all levels, and distal axonal atrophy. Motor end-plates reveal small or absent nerve terminals. Subclinical non-motor system involvement includes neuronal loss in Clarke's nucleus and dorsal root ganglia, degeneration of non-motor tracts in the spinal cord, loss of receptors in the dorsal horns of the spinal cord, and myelinated fiber loss with segmental demyelination in sensory and mixed nerves. The serious implications of the diagnosis of ALS make it mandatory to exclude similar potentially treatable disorders. Management should be multidisciplinary, and discussions with the patient and family members should be frank and frequent. Discussions about ventilatory support should take place early in the disease so that death from respiratory failure can be prevented, when that is desired, and conversely to obviate the discontent and anger that accompany involuntary life on a ventilator.

Entities:  

Mesh:

Year:  1985        PMID: 4051456     DOI: 10.1002/ana.410180302

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  72 in total

1.  Axonal swellings in the corticospinal tracts in amyotrophic lateral sclerosis.

Authors:  K Okamoto; S Hirai; M Shoji; Y Senoh; T Yamazaki
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Association of amyotrophic lateral sclerosis, Hoigne's syndrome and residence in Guam.

Authors:  P O Behan; A M Bakheit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

3.  Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40.

Authors:  C Jenkinson; R Fitzpatrick; C Brennan; M Bromberg; M Swash
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

4.  Magnetic resonance imaging in motor neuron disease.

Authors:  M L Luís; A Hormigo; C Maurício; M M Alves; R Serrão
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

5.  Management of symptoms in amyotrophic lateral sclerosis.

Authors:  Lisa S Thibodeaux; Amparo Gutierrez
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

Review 6.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

7.  Age and founder effect of SOD1 A4V mutation causing ALS.

Authors:  M Saeed; Y Yang; H-X Deng; W-Y Hung; N Siddique; L Dellefave; C Gellera; P M Andersen; T Siddique
Journal:  Neurology       Date:  2009-01-28       Impact factor: 9.910

8.  Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Authors:  Edward J Kasarskis; Marta S Mendiondo; Dwight E Matthews; Hiroshi Mitsumoto; Rup Tandan; Zachary Simmons; Mark B Bromberg; Richard J Kryscio
Journal:  Am J Clin Nutr       Date:  2014-02-12       Impact factor: 7.045

9.  The impact of gradient strength on in vivo diffusion MRI estimates of axon diameter.

Authors:  Susie Y Huang; Aapo Nummenmaa; Thomas Witzel; Tanguy Duval; Julien Cohen-Adad; Lawrence L Wald; Jennifer A McNab
Journal:  Neuroimage       Date:  2014-12-09       Impact factor: 6.556

10.  Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis.

Authors:  Francois Gros-Louis; Peter M Andersen; Nicolas Dupre; Makoto Urushitani; Patrick Dion; Frederique Souchon; Monique D'Amour; William Camu; Vincent Meininger; Jean-Pierre Bouchard; Guy A Rouleau; Jean-Pierre Julien
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.